Clinical Trials · NCT05982093

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

Name: Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingPhase 2Gonadorelin

Phase: Phase 2
Recruitment status: Recruiting
Sponsor: SOLTI Breast Cancer Research Group
Enrollment: 96
Start date: Feb 2023
Locations: 15 sites, Spain
Primary endpoint: To evaluate the biological activity of elacestrant with or without OFS in premenopausal women with ER+/HER2- operable EBC

View Gonadorelin compound reference